Economic studies have shown promising positive evidence of cost-saving and/or cost-effectiveness of implementing early treatment of renin-angiotensin system inhibitors (RAS) drugs to prevent the progression of nephropathy in patients comorbid with diabetes and hypertension [4, 6, 7, 9–16]. This evidence concerns the gene REN and kidney disorder.